Biotech IPO window opening, but big pharma M&A still drives dealmaking

Top bankers indicate that while the biotech IPO window is beginning to open, mergers and acquisitions by large pharmaceutical companies remain the primary driver of dealmaking, fueled by the need to replenish drug pipelines ahead of patent expirations.